{
  "consolidation_metadata": {
    "timestamp": "2025-10-01T11:05:42.034321",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "consolidation_type": "picos",
    "data_split": "test",
    "total_consolidated_picos": 84,
    "source_countries": [
      "AT",
      "BE",
      "CZ",
      "DE",
      "DK",
      "EN",
      "ES",
      "EU",
      "FR",
      "IT",
      "NL",
      "PO",
      "PT",
      "SE"
    ],
    "source_types": [
      "clinical_guideline",
      "hta_submission"
    ]
  },
  "consolidated_picos": [
    {
      "Population": "adults with HCC in Barcelona Clinic Liver Cancer (BCLC) stage B or C who did not receive any prior systemic therapy for the advanced or inoperable disease. Hepatic cirrhosis of any aetiology was not an exclusion criterion. Patients in BCLC stage B had to be ineligible for transarterial chemoembolization (TACE). Further inclusion criteria were Child-Pugh stage A and an Eastern Cooperative Oncology Group – Performance Status (ECOG-PS) score of 0 or 1.",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "AT",
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        1,
        21
      ],
      "Occurrence_Count": 2,
      "Grouping_Key": {
        "population": "adults with HCC in Barcelona Clinic Liver Cancer (BCLC) stage B or C who did not receive any prior systemic therapy for the advanced or inoperable disease. Hepatic cirrhosis of any aetiology was not an exclusion criterion. Patients in BCLC stage B had to be ineligible for transarterial chemoembolization (TACE). Further inclusion criteria were Child-Pugh stage A and an Eastern Cooperative Oncology Group – Performance Status (ECOG-PS) score of 0 or 1.",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "patients with advanced HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "TACE",
      "Countries": [
        "AT",
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        2,
        22
      ],
      "Occurrence_Count": 2,
      "Grouping_Key": {
        "population": "patients with advanced HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "TACE"
      }
    },
    {
      "Population": "patients with advanced HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "TACE + Sorafenib",
      "Countries": [
        "AT",
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        3,
        23
      ],
      "Occurrence_Count": 2,
      "Grouping_Key": {
        "population": "patients with advanced HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "TACE + Sorafenib"
      }
    },
    {
      "Population": "patients with advanced HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "arterial embolization",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        4
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "arterial embolization"
      }
    },
    {
      "Population": "patients with advanced HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "arterial embolization with an antitumor drug (any type of embolization material or antitumor drug)",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        5
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "arterial embolization with an antitumor drug (any type of embolization material or antitumor drug)"
      }
    },
    {
      "Population": "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "local hepatic therapies (ablation, embolization, and radiotherapy)",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        6
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
        "intervention": "Medicine X (under assessment)",
        "comparator": "local hepatic therapies (ablation, embolization, and radiotherapy)"
      }
    },
    {
      "Population": "patients with HCC who are not otherwise candidates for surgical resection or transplantation with no evidence of extrahepatic disease",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "liver-directed therapies",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        7
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with HCC who are not otherwise candidates for surgical resection or transplantation with no evidence of extrahepatic disease",
        "intervention": "Medicine X (under assessment)",
        "comparator": "liver-directed therapies"
      }
    },
    {
      "Population": "patients with intermediate-stage hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "supportive care",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        8
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with intermediate-stage hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "supportive care"
      }
    },
    {
      "Population": "patients with intermediate-stage hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "systemic chemotherapy",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        9
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with intermediate-stage hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "systemic chemotherapy"
      }
    },
    {
      "Population": "patients with intermediate-stage hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "TACE",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        10
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with intermediate-stage hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "TACE"
      }
    },
    {
      "Population": "patients with intermediate-stage hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "TAE",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        11
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with intermediate-stage hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "TAE"
      }
    },
    {
      "Population": "patients with intermediate-stage hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "radiofrequency ablation",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        12
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with intermediate-stage hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "radiofrequency ablation"
      }
    },
    {
      "Population": "patients with intermediate-stage hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "microwave ablation",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        13
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with intermediate-stage hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "microwave ablation"
      }
    },
    {
      "Population": "patients with intermediate-stage hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "other ablations (laser ablation, cryoablation, HIFU, irreversible electroporation)",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        14
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with intermediate-stage hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "other ablations (laser ablation, cryoablation, HIFU, irreversible electroporation)"
      }
    },
    {
      "Population": "patients with intermediate-stage hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "alcohol injection",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        15
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with intermediate-stage hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "alcohol injection"
      }
    },
    {
      "Population": "patients with intermediate-stage hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "acetic acid injection",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        16
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with intermediate-stage hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "acetic acid injection"
      }
    },
    {
      "Population": "patients with intermediate-stage hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "radiotherapy (stereotactic body radiotherapy or radioembolisation)",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        17
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with intermediate-stage hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "radiotherapy (stereotactic body radiotherapy or radioembolisation)"
      }
    },
    {
      "Population": "patients with intermediate-stage hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "liver resection",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        18
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with intermediate-stage hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "liver resection"
      }
    },
    {
      "Population": "patients with intermediate-stage hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "liver transplantation",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        19
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with intermediate-stage hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "liver transplantation"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "Best Supportive Care",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        20
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "Best Supportive Care"
      }
    },
    {
      "Population": "HCC patients with PVT",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "TACE",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        24
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "HCC patients with PVT",
        "intervention": "Medicine X (under assessment)",
        "comparator": "TACE"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "best supportive care",
      "Countries": [
        "DE",
        "AT",
        "FR"
      ],
      "Source_Types": [
        "hta_submission",
        "clinical_guideline"
      ],
      "Source_Refs": [
        25,
        51,
        59,
        71
      ],
      "Occurrence_Count": 4,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "best supportive care"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "supportive care",
      "Countries": [
        "DE",
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        26,
        8
      ],
      "Occurrence_Count": 2,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "supportive care"
      }
    },
    {
      "Population": "treatment naive adult (aged ≥18 years) patients with advanced, unresectable or metastatic hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "DK"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        27
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "treatment naive adult (aged ≥18 years) patients with advanced, unresectable or metastatic hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "patients with unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "DK",
        "ES",
        "PT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        28,
        32,
        42,
        43
      ],
      "Occurrence_Count": 4,
      "Grouping_Key": {
        "population": "patients with unresectable hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "Adult patients with advanced HCC and adult patients with inoperable HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "DK"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        29
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "Adult patients with advanced HCC and adult patients with inoperable HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "adults with advanced or unresectable HCC in adults with Child-Pugh grade A liver impairment and an ECOG performance status of 0 or 1, who have not had previous systemic treatment",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "EN"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        30
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adults with advanced or unresectable HCC in adults with Child-Pugh grade A liver impairment and an ECOG performance status of 0 or 1, who have not had previous systemic treatment",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "adults with advanced or unresectable HCC in adults with Child-Pugh grade A liver impairment and an ECOG performance status of 0 or 1, who have not had previous systemic treatment",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "lenvatinib",
      "Countries": [
        "EN"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        31
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adults with advanced or unresectable HCC in adults with Child-Pugh grade A liver impairment and an ECOG performance status of 0 or 1, who have not had previous systemic treatment",
        "intervention": "Medicine X (under assessment)",
        "comparator": "lenvatinib"
      }
    },
    {
      "Population": "patients with unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "lenvatinib",
      "Countries": [
        "ES"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        33
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with unresectable hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "lenvatinib"
      }
    },
    {
      "Population": "patients with advanced and/ or unresectable hepatocarcinoma, Child-Pugh EMI, in the absence of grade 0 or grade 3-4",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "ES"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        34
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced and/ or unresectable hepatocarcinoma, Child-Pugh EMI, in the absence of grade 0 or grade 3-4",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "patients aged 18 years or older and diagnosed with locally advanced or metastatic and/ or unresectable HCC with histological/ cytological confirmation or clinical features consistent with the American Association for the Study of the Liver (AASLD) criteria in cirrhotic patients",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "ES"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        35
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients aged 18 years or older and diagnosed with locally advanced or metastatic and/ or unresectable HCC with histological/ cytological confirmation or clinical features consistent with the American Association for the Study of the Liver (AASLD) criteria in cirrhotic patients",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "patients with advanced or untreatable first-line CHC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "ES"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        36
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or untreatable first-line CHC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "patients with advanced or untreatable first-line CHC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "lenvatinib",
      "Countries": [
        "ES"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        37
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or untreatable first-line CHC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "lenvatinib"
      }
    },
    {
      "Population": "patients with Child- Pugh C or Child-Pugh B with decompensations associated with poor prognosis such as refractory ascites, recurrent hepatic encephalopathy, spontaneous bacterial peritonitis, etc. They are characterised by deterioration of general condition and/or severely impaired hepatic function with median survival not exceeding four months",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "best supportive care",
      "Countries": [
        "ES"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        38
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with Child- Pugh C or Child-Pugh B with decompensations associated with poor prognosis such as refractory ascites, recurrent hepatic encephalopathy, spontaneous bacterial peritonitis, etc. They are characterised by deterioration of general condition and/or severely impaired hepatic function with median survival not exceeding four months",
        "intervention": "Medicine X (under assessment)",
        "comparator": "best supportive care"
      }
    },
    {
      "Population": "adult patients with advanced or unresectable hepatocellular carcinoma (HCC) (stage BCLC B or C) who have not received prior systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        39
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adult patients with advanced or unresectable hepatocellular carcinoma (HCC) (stage BCLC B or C) who have not received prior systemic therapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "patients with advanced hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "placebo",
      "Countries": [
        "NL"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        40
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "placebo"
      }
    },
    {
      "Population": "patients with hepatocellular carcinoma in whom initiation of curative treatment or (continuation) of locoregional or local palliative treatment is not possible or considered medically inappropriate (hepatocell carcinomas)",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "best care regimen available",
      "Countries": [
        "NL"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        41
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with hepatocellular carcinoma in whom initiation of curative treatment or (continuation) of locoregional or local palliative treatment is not possible or considered medically inappropriate (hepatocell carcinomas)",
        "intervention": "Medicine X (under assessment)",
        "comparator": "best care regimen available"
      }
    },
    {
      "Population": "adult patients with advanced or non-resectable hepatocellular carcinoma (HCC) and who have not received any previous systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "PT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        42
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adult patients with advanced or non-resectable hepatocellular carcinoma (HCC) and who have not received any previous systemic therapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "patients with unresectable HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "chemoembolization (with doxorubicin or cisplatin)",
      "Countries": [
        "BE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [
        53
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with unresectable HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "chemoembolization (with doxorubicin or cisplatin)"
      }
    },
    {
      "Population": "patients with unresectable HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "radioactive Iodine 131 treatment",
      "Countries": [
        "BE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [
        54
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with unresectable HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "radioactive Iodine 131 treatment"
      }
    },
    {
      "Population": "patients with unresectable HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "systemic chemotherapy (doxorubicin or cisplatin)",
      "Countries": [
        "BE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [
        55
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with unresectable HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "systemic chemotherapy (doxorubicin or cisplatin)"
      }
    },
    {
      "Population": "patients with unresectable HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "hormonal therapy with tamoxifen",
      "Countries": [
        "BE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [
        56
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with unresectable HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "hormonal therapy with tamoxifen"
      }
    },
    {
      "Population": "patients with unresectable HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "subcutaneous octreotide therapy",
      "Countries": [
        "BE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [
        57
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with unresectable HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "subcutaneous octreotide therapy"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "Sorafenib",
      "Countries": [
        "AT",
        "DE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [
        50,
        58
      ],
      "Occurrence_Count": 2,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "Sorafenib"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma who have not received durvalumab in the first line",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "pembrolizumab",
      "Countries": [
        "AT",
        "DE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [
        52,
        60
      ],
      "Occurrence_Count": 2,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma who have not received durvalumab in the first line",
        "intervention": "Medicine X (under assessment)",
        "comparator": "pembrolizumab"
      }
    },
    {
      "Population": "advanced disease, systemic treatment should be offered to patients with ECOG/PS 0-1 and Child–Pugh class A",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "BSC best supportive care",
      "Countries": [
        "ES"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [
        61
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "advanced disease, systemic treatment should be offered to patients with ECOG/PS 0-1 and Child–Pugh class A",
        "intervention": "Medicine X (under assessment)",
        "comparator": "BSC best supportive care"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [
        62
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "lenvatinib",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [
        63
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "lenvatinib"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "atezolizumab plus bevacizumab",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [
        64
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "atezolizumab plus bevacizumab"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma who progressed on sorafenib treatment",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "regorafenib",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [
        65
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma who progressed on sorafenib treatment",
        "intervention": "Medicine X (under assessment)",
        "comparator": "regorafenib"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma who progressed on sorafenib treatment",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "cabozantinib",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [
        66
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma who progressed on sorafenib treatment",
        "intervention": "Medicine X (under assessment)",
        "comparator": "cabozantinib"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma and increased alpha-fetoprotein concentrations following first-line sorafenib",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "ramucirumab",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [
        67
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma and increased alpha-fetoprotein concentrations following first-line sorafenib",
        "intervention": "Medicine X (under assessment)",
        "comparator": "ramucirumab"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma previously treated with sorafenib",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "nivolumab plus ipilimumab",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [
        68
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma previously treated with sorafenib",
        "intervention": "Medicine X (under assessment)",
        "comparator": "nivolumab plus ipilimumab"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "selective internal radiation therapy (SIRT)",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [
        69
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "selective internal radiation therapy (SIRT)"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "transarterial chemoembolization (TACE)",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [
        70
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "transarterial chemoembolization (TACE)"
      }
    },
    {
      "Population": "cirrhotic (max Child-Pugh B) patients with unresectable M0 multi-nodular HCC, in the absence of portal thrombosis",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "TACE",
      "Countries": [
        "IT"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [
        72
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "cirrhotic (max Child-Pugh B) patients with unresectable M0 multi-nodular HCC, in the absence of portal thrombosis",
        "intervention": "Medicine X (under assessment)",
        "comparator": "TACE"
      }
    },
    {
      "Population": "Non-locally-treatable patients with a diagnosis of hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "NL"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [
        73
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "Non-locally-treatable patients with a diagnosis of hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "Non-locally-treatable patients with a diagnosis of hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "atezolizumab with bevacizumab",
      "Countries": [
        "NL"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [
        74
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "Non-locally-treatable patients with a diagnosis of hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "atezolizumab with bevacizumab"
      }
    },
    {
      "Population": "patients with non-surgical hepatocellular carcinoma in good general condition and with good liver function (Child and Pugha Class A)",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "combination of bevacizumab and atezolizumab",
      "Countries": [
        "PO"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [
        75
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with non-surgical hepatocellular carcinoma in good general condition and with good liver function (Child and Pugha Class A)",
        "intervention": "Medicine X (under assessment)",
        "comparator": "combination of bevacizumab and atezolizumab"
      }
    },
    {
      "Population": "patients previously treated with Sorafenib with AFP ≥ 400 ng/ ml",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "ramucyrumab",
      "Countries": [
        "PO"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [
        76
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients previously treated with Sorafenib with AFP ≥ 400 ng/ ml",
        "intervention": "Medicine X (under assessment)",
        "comparator": "ramucyrumab"
      }
    },
    {
      "Population": "patients who are well tolerant of sorafenib",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "regorafenib",
      "Countries": [
        "PO"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [
        77
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients who are well tolerant of sorafenib",
        "intervention": "Medicine X (under assessment)",
        "comparator": "regorafenib"
      }
    },
    {
      "Population": "second-line patients who have previously received bevacizumab with atezolizumab",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "PO"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [
        78
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "second-line patients who have previously received bevacizumab with atezolizumab",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "second-line patients who have previously received bevacizumab with atezolizumab",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "leninivat",
      "Countries": [
        "PO"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [
        79
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "second-line patients who have previously received bevacizumab with atezolizumab",
        "intervention": "Medicine X (under assessment)",
        "comparator": "leninivat"
      }
    },
    {
      "Population": "second-line patients who have previously received bevacizumab with atezolizumab",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "cabozantinib",
      "Countries": [
        "PO"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [
        80
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "second-line patients who have previously received bevacizumab with atezolizumab",
        "intervention": "Medicine X (under assessment)",
        "comparator": "cabozantinib"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A) without contraindications to the medicinal products",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "atezolizumab and bevacizumab",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [
        81
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A) without contraindications to the medicinal products",
        "intervention": "Medicine X (under assessment)",
        "comparator": "atezolizumab and bevacizumab"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A) when combination therapy is inappropriate",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "tremelimumab-durvalumab combination",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [
        82
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A) when combination therapy is inappropriate",
        "intervention": "Medicine X (under assessment)",
        "comparator": "tremelimumab-durvalumab combination"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A) who cannot be offered atezolizumab, bevacizumab or tremelimumab",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "lenvatinib",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [
        83
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A) who cannot be offered atezolizumab, bevacizumab or tremelimumab",
        "intervention": "Medicine X (under assessment)",
        "comparator": "lenvatinib"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A) who cannot be offered atezolizumab, bevacizumab or tremelimumab",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [
        84
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A) who cannot be offered atezolizumab, bevacizumab or tremelimumab",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "adult patients with advanced or non-resettable HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "Tecentriq (atezolizumab) plus bevacizumab",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        44
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adult patients with advanced or non-resettable HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "Tecentriq (atezolizumab) plus bevacizumab"
      }
    },
    {
      "Population": "adult patients with advanced or non-resettable HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        45
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adult patients with advanced or non-resettable HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "adult patients with advanced or non-resettable HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "Lenvima (lenvatinib)",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        46
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adult patients with advanced or non-resettable HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "Lenvima (lenvatinib)"
      }
    },
    {
      "Population": "patients with HCC with non-viral etiologies",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "Tecentriq plus bevacizumab",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        47
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with HCC with non-viral etiologies",
        "intervention": "Medicine X (under assessment)",
        "comparator": "Tecentriq plus bevacizumab"
      }
    },
    {
      "Population": "patients for whom treatment with atezoumab plus bevacizumab is inappropriate",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        48
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients for whom treatment with atezoumab plus bevacizumab is inappropriate",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "patients for whom treatment with atezoumab plus bevacizumab is inappropriate",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "lenvatinib",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [
        49
      ],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients for whom treatment with atezoumab plus bevacizumab is inappropriate",
        "intervention": "Medicine X (under assessment)",
        "comparator": "lenvatinib"
      }
    }
  ]
}